
Evolus (EOLS) Stock Forecast & Price Target
Evolus (EOLS) Analyst Ratings
Bulls say
Evolus is a high-growth company with a differentiated approach in the medical aesthetics market, targeting millennials and bypassing third-party payer dynamics. With Jeuveau, they hold a strong 14% market share in the US and expanding presence overseas. Their recent launch of new products and strong balance sheet position them well for future growth. However, potential risks include competition, pricing pressure, and regulatory delays.
Bears say
Evolus is facing multiple headwinds, including a highly competitive market for injectable aesthetic products, with Botox being the dominant player. The company's heavy reliance on Evolysse, which has yet to gain significant market traction, also adds to its vulnerability. In addition, Evolus' financials show a substantial amount of debt and reliance on equity offerings, indicating a precarious financial position.
This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.
Evolus (EOLS) Analyst Forecast & Price Prediction
Start investing in Evolus (EOLS)
Order type
Buy in
Order amount
Est. shares
0 shares